Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer
- 20 May 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (15), 2086-2092
- https://doi.org/10.1200/jco.2006.08.3998
Abstract
Purpose Single-agent intravenous (IV) topotecan is an effective treatment for small-cell lung cancer (SCLC) after failure of first-line chemotherapy. This open-label, randomized, phase III study compared oral and IV topotecan in patients with SCLC sensitive to initial chemotherapy. Patients and Methods Patients with limited- or extensive-disease SCLC, documented complete or partial response to first-line therapy, Eastern Cooperative Oncology Group performance status ≤ 2, and measurable recurrent disease (WHO criteria) with a treatment-free interval of ≥ 90 days were assigned to treatment with either oral topotecan 2.3 mg/m2/d on days 1 through 5 or IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days. Primary end point was response rate as confirmed by an external reviewer blinded to treatment. Results A total of 309 patients were randomly assigned. In intent-to-treat analysis, response rates were 18.3% with oral topotecan (n = 153) and 21.9% with IV topotecan (n = 151), with a difference (oral –IV)...Keywords
This publication has 20 references indexed in Scilit:
- Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results DatabaseJournal of Clinical Oncology, 2006
- Factors affecting pharmacokinetic variability of oral topotecan: a population analysisBritish Journal of Cancer, 2004
- Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918Journal of Clinical Oncology, 2002
- Small Cell Lung Cancer: Current Therapy and Promising New RegimensThe Oncologist, 2002
- Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung CancerJournal of Clinical Oncology, 2001
- 1041: Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)European Journal Of Cancer, 1997
- 126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II studyLung Cancer, 1997
- Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.Journal of Clinical Oncology, 1997
- Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitorBritish Journal of Cancer, 1996
- In this issueAnnals of Oncology, 1996